Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion CohortLaura Q.M. Chow, Tanguy Y. Seiwert, Ranee Mehra et al.|Journal of Clinical Oncology|2016Cited by 859
Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort.Tanguy Y. Seiwert, Laura Q.M. Chow, Robert I. Haddad et al.|Journal of Clinical Oncology|2015Cited by 103